Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Gait ataxia, Severe intellectual disability, Intellectual disability, and Global developmental delay; and very common findings: Absent speech. 36 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 11 | Inability to walk, Seizure, Gait ataxia |
Head and neck | 4 | Tented upper lip vermilion, Facial hypotonia, Microcephaly |
Muscles | 3 | Low muscle tone (hypotonia), Facial hypotonia, Delayed gross motor development |
Eyes | 2 | Cerebral visual impairment, Visual impairment |
Bones and joints | 2 | Sideways curvature of the spine (scoliosis), Joint hypermobility |
Kidneys and urinary system | 1 | Unilateral renal agenesis |
Digestive system | 1 | Chronic constipation |
Arms and legs | 1 | Deviation of the 5th finger |
Age of onset: at birth.
To date, fewer than 50 individuals have been identified with a pathogenic variant in PPP2R1A [, , , , ]. The following description of the phenotypic features associated with this condition is based on comprehensive clinical observations of individuals with confirmed pathogenic variants. Table 2. Select Features of PPP2R1A-Related Neurodevelopmental Disorder
Feature | # of Persons w/Feature / # Assessed | Comment |
|---|---|---|
Developmental delay | 37/37 (100%) | Ranging from mild to profound |
Language delay | 37/37 (100%) | Some persons remain nonverbal. |
Intellectual disability | 36/37 (97%) | Ranging from mild to profound, usually moderate to severe |
Delayed walking | 28/30 (93%) | Some persons remain nonambulatory. |
Hypotonia | 32/35 (91%) | Persistent into childhood adulthood in 2 known persons |
Corpus callosum hypo-/aplasia | 22/33 (67%) | — |
Head growth abnormalities | 22/36 (61%) | — |
Macrocephaly | 12/36 (33%) | See . |
Microcephaly | 10/36 (28%) Feeding difficulties | 15/30 (50%) |
Epilepsy | 17/35 (49%) | See . |
Ventriculomegaly | 14/33 (42%) | Incl hydrocephalus |
Joint hypermobility | 14/37 (38%) | — |
External ear abnormalities | 11/37 (30%) | Incl microtia |
Scoliosis | 9/37 (24%) | — |
Delayed myelination | 6/33 (18%) | — |
Hypoplasia of cerebellum/ brain stem | 5/33 (15%) | — |
Periventricular leukomalacia | 4/33 (12%) | — |
Hearing loss | 4/37 (11%) | Incl sensorineural hearing loss assoc w/microtia |
Short stature | 3/37 (8%) | — |
Persistent ductus arteriosus | 3/37 (8%) | Developmental delay (DD) and intellectual disability (ID). The degree of DD is variable, but often in the moderate-to-severe range. DD in most affected individuals is global, affecting both cognitive and motor skills, but speech and language development and walking appear to be especially delayed. |
Source: GeneReviews — "PPP2R1A-Related Neurodevelopmental Disorder"
PPP2R1A function has not been fully characterized.
Houge-Janssens syndrome 2 is associated with mutations in the PPP2R1A gene on chromosome 19.
No consensus clinical diagnostic criteria for PPP2R1A-related neurodevelopmental disorder (PPP2R1A-NDD) have been published to date.
PPP2R1A-related neurodevelopmental disorder (PPP2R1A-NDD) should be considered in individuals with the following clinical and brain imaging findings. Clinical findings include:
Mild-to-profound developmental delay and/or intellectual disability
Delayed walking
Language delay
Generalized hypotonia, postnatal/infantile onset
AND any of the following features presenting in infancy or childhood:
Feeding problems
Abnormal head circumference (macrocephaly/microcephaly)
Epilepsy
Behavioral problems: attention-deficit/hyperactivity disorder, autism spectrum disorder, self-injurious behavior, anxiety, destructive behaviors
Joint hypermobility
Source: GeneReviews — "PPP2R1A-Related Neurodevelopmental Disorder"
Head circumference abnormalities. The wide variability of head circumference abnormalities observed in PPP2R1A-related neurodevelopmental disorder (PPP2R1A-NDD) is reminiscent of RAC1-related intellectual disability and TRIO-related intellectual disability (Trio acts as a Rac1 modulator) . Overgrowth. Individuals with macrocephaly and a heterozygous PPP2R1A pathogenic variant that does not affect PPP2R1A binding have features reminiscent of overgrowth syndromes, both within the overgrowth and intellectual disability spectrum (e.g., Weaver syndrome; see EZH2-Related Overgrowth) and in the spectrum of disorders associated with disruption of the PI3K/AKT/mTOR tyrosine receptor kinase pathway (e.g., MCAP syndrome; see PIK3CA-Related Overgrowth Spectrum) . See for additional disorders to consider in the differential diagnosis of PPP2R1A-NDD. Table 3. Selected Disorders of Interest in the Differential Diagnosis of PPP2R1A-Related Neurodevelopmental Disorder
Gene | DiffDx Disorder | MOI | Features Observed in DiffDx Disorder PPP2R1A-NDD |
|---|
Genetic testing for PPP2R1A is available. Testing is considered confirmatory for diagnosis.
No approved treatments are currently available for Houge-Janssens syndrome 2. The disease remains an area of unmet medical need.
No clinical practice guidelines for PPP2R1A-related neurodevelopmental disorder (PPP2R1A-NDD) have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with PPP2R1A-NDD, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with PPP2R1A-Related Neurodevelopmental Disorder
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Measurement of growth parameters | To incl weight, length/height, head circumference to assess for failure to thrive, short stature, and macro- or microcephaly, respectively |
Neurologic | Neurologic eval | To incl brain MRI; Consider EEG if seizures are a concern. |
Development | Developmental assessment | To incl motor, adaptive, cognitive, speech/language evals; Eval for early intervention/ special education Psychiatric/ |
Behavioral | Neuropsychiatric eval | For persons age 12 mos: screening for behavioral concerns incl sleep disturbances, ADHD, anxiety, /or traits suggestive of ASD Gastrointestinal/ |
Feeding | Gstroenterology/ nutrition/ feeding team eval |
Source: GeneReviews — "PPP2R1A-Related Neurodevelopmental Disorder"
View trials for Houge-Janssens syndrome 2
Table 6. Recommended Surveillance for Individuals with PPP2R1A-Related Neurodevelopmental Disorder
System/Concern | Evaluation | Frequency |
|---|---|---|
ENT | Dental eval | At least annually after eruption of teeth or as clinically indicated |
Hearing | Audiology eval | Annually in childhood or as clinically indicated Psychiatric/ |
Behavioral | Behavioral assessment for anxiety, attention, aggressive or self-injurious behavior | As clinically indicated Family/ |
Community | Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources) care coordination. | At each visit GERD = gastroesophageal reflux disease; OT = occupational therapy; PT = physical therapy |
Source: GeneReviews — "PPP2R1A-Related Neurodevelopmental Disorder"
Phenotype severity distribution: 4 always present features, 1 very common feature, 21 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Houge-Janssens syndrome 2.
18 publications have been identified in PubMed for Houge-Janssens syndrome 2. Research spans Review / Meta-Analysis (38%), Case Report / Case Series (25%), and Clinical Trial Publication (19%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 6 | 38% |
Patient case studies | 4 | 25% |
Clinical study results | 3 | 19% |
Laboratory research | 2 | 13% |
Disease patterns and progression | 1 | 6% |
Wang Z (2026). [PMID: 41916888](https://pubmed.ncbi.nlm.nih.gov/41916888/). *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. [Review / Meta-Analysis]
van der Leij M (2026). [PMID: 41680088](https://pubmed.ncbi.nlm.nih.gov/41680088/). *American journal of medical genetics. Part A*. [Review / Meta-Analysis]
Kayhan G (2026). [PMID: 41751633](https://pubmed.ncbi.nlm.nih.gov/41751633/). *Genes*. [Basic Science / Preclinical]
Verbinnen I (2025). [PMID: 39978342](https://pubmed.ncbi.nlm.nih.gov/39978342/). *American journal of human genetics*. [Review / Meta-Analysis]
Liu M (2025). [PMID: 39994654](https://pubmed.ncbi.nlm.nih.gov/39994654/). *BMC medical genomics*. [Epidemiology / Natural History]
Hu J (2025). [PMID: 40781915](https://pubmed.ncbi.nlm.nih.gov/40781915/). *Molecular genetics & genomic medicine*. [Case Report / Case Series]
Lee J (2025). [PMID: 41465181](https://pubmed.ncbi.nlm.nih.gov/41465181/). *Genes*. [Review / Meta-Analysis]
Mania-Pâris L (2025). [PMID: 40450402](https://pubmed.ncbi.nlm.nih.gov/40450402/). *Revue neurologique*. [Review / Meta-Analysis]
Zarante-Bahamon AM (2025). [PMID: 40073204](https://pubmed.ncbi.nlm.nih.gov/40073204/). *Clinical dysmorphology*. [Basic Science / Preclinical]
Houge GD (2025). [PMID: 40555839](https://pubmed.ncbi.nlm.nih.gov/40555839/). *European journal of human genetics : EJHG*. [Review / Meta-Analysis]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 5:21 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Houge-Janssens syndrome 2
AKT3 | MPPH syndrome 2 | AD | Megalencephaly, epilepsy, hypotonia | Polydactyly, hydrocephalus, polymicrogyria in MPPH2 |
CCND2 | MPPH syndrome 3 | AD | Megalencephaly, epilepsy | Polydactyly, hydrocephalus, polymicrogyria in MPPH3 |
EZH2 | Weaver syndrome (See EZH2-Related Overgrowth.) | AD | Macrocephaly, seizures, frontal bossing, long face, ventriculomegaly, behavioral difficulties | prenatal/postnatal length, advanced bone age, umbilical hernias are common in persons w/Weaver syndrome. NSD1 |
Sotos syndrome | AD | Macrocephaly, neonatal hypotonia, large head, corpus callosum hypoplasia, large ventricles | prenatal/postnatal length advanced bone age are common in persons w/Sotos syndrome. | — |
PIK3CA | MCAP syndrome (See PIK3CA-Related Overgrowth Spectrum.) | See footnote 1. | Megalencephaly, ventriculomegaly, hypotonia | Polymicrogyria, polydactyly in MCAP syndrome |
PIK3R2 | MPPH syndrome 1 | AD | Megalencephaly, epilepsy | Polydactyly, polymicrogyria in MPPH1 |
PPP2CA | PPP2CA-related NDD (OMIM 618354) | AD | Hypotonia, delayed walking speech, Macro-/microcephaly, corpus callosum hypoplasia, enlarged ventricles | None PPP2R5D |
PPP2R5D-related NDD | AD | Hypotonia, macrocephaly, frontal bossing, elongated face, large ventricles | Corpus callosum aplasia is more common in PPP2R1A-NDD. | — |
RAC1 | RAC1-related ID (OMIM 617751) | AD | Macro-/microcephaly, dysplastic ears, moderate-to-severe DD, seizures, enlarged ventricles | Possibly different facial dysmorphology, but otherwise none TRIO |
TRIO-related ID | AD | Macro-/microcephaly, ID, behavioral manifestations, scoliosis | Hand foot skeletal abnormalities in TRIO-ID AD = autosomal dominant; DD = developmental delay; DiffDx = differential diagnosis; ID = intellectual disability; MCAP = megalencephaly-capillary malf... | — |
Source: GeneReviews — "PPP2R1A-Related Neurodevelopmental Disorder"
Musculoskeletal | Orthopedics/ physical medicine rehab/ PT OT eval | To incl assessment of:; Gross motor fine motor skills; Scoliosis; Mobility, ADL, need for adaptive devices; Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills) |
Hearing | Audiology eval | To assess for hearing loss |
ENT/Mouth | Assessment for ear anomalies, incl microtia | Consider referral to ENT specialist when present. Eval by dentist if teeth have erupted |
Cardiovascular | Clinical assessment for congenital cardiac issues, such as PDA | Consider referral to cardiologist as clinically indicated. |
Eyes | Assessment for ptosis | Consider referral to ophthalmologist if present. Genetic |
counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of PPP2R1A-NDD to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with PPP2R1A-Related Neurodevelopmental Disorder Manifestation/Concern | Treatment | Considerations/Other |
Epilepsy | Standardized treatment w/ASM by experienced neurologist | Many ASMs may be effective; none has been demonstrated effective specifically for this disorder.; Some affected persons have epilepsy that is refractory to ASM therapy or may require multiple ASMs.; Education of parents/caregivers1 Developmental delay / Intellectual disability / |
Behavioral | See . | Poor weight gain / Failure to thrive |
Scoliosis | Standard treatment per orthopedist | — |
Hearing | Hearing aids may be helpful; per otolaryngologist. | Community hearing services through early intervention or school district |
Ear anomalies | Standard treatment per otolaryngologist | Most ear anomalies are minor do not require surgical intervention. |
Dental crowding | Standard treatment per dentist | — |
Congenital heart defects | Standard treatment per cardiologist | Most described heart defects to date have not required surgical intervention. |
Ptosis | Standard treatment per ophthalmologist | Family/Community |